Examples of CYT387 in a sentence
Treated explants were cultured in ex vivo medium contain- ing CYT387 (10 µM).
Once palpable tumours were detected at an average volume of 100 mm3, CYT387 was administered via daily oral gavage at a dose of 100 mg/kg or vehicle con- trol.
These interim data demonstrated that CYT387 was generally safe, well tolerated and was able to reduce spleen size and improve constitutional symptoms in patients with a degree of efficacy comparable to other JAK-targeting molecules in late-stage development.
Administration of a potent JAK1/2 and TBK1/IKKε inhib- itor (CYT387) that inhibits both STAT and nuclear factor kB (NF-kB) signaling to mice significantly decreased MHC class II expression in Lgr5+ ISCs compared with vehicle-treated con- trols (Figures 5F–5I, S3H, and S3I) (Tyner et al., 2010).
We next asked whether IFNg-induced epithelial MHC class II expression is inhibited by CYT387 in in vitro organoid assays and found that CYT387 blunted the induction of MHC class II expression in response to IFNg (Figure 5J).
Representative flow cytometry histogram plots of MHC class II expression in Lgr5+ ISCs (I).(J) Relative expression of MHC class II (H2-Ab1) in intestinal organoids treated with or without CYT387 and/or IFNg (n = 5, mean ± SEM).(K) Relative expression of MHC class II (H2-Ab1) in Epcam+ cells isolated from crypts of control or IFNGR1 KO (n = 5, mean ± SEM).*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t tests).
However, YM may decide to advance CYT387 further on its own in order to enhance long-term shareholder value.
MMB dihydrochloride (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4- yl)benzamide, CYT387, GS-0387) is a novel, weakly basic, disubstituted pyrimidine compound molecular weight of 487.38 Da. The free base is poorly soluble in water.
The Company is also conducting Business Development activities for CYT387, exploring potential opportunities to further develop and/or commercialize CYT387 through partnerships with other companies.
We are governed by the corporate laws in Nova Scotia, Canada which in some cases have a different effect on shareholders than the corporate laws in Delaware, U.S. OUTLOOKCYT387Having reported positive interim data in December 2011 from a 166 patient Phase I/II trial of CYT387 in myelofibrosis, YM conducted productive discussions with regulatory authorities in the US and Europe which have affirmed the range of options available for the pivotal program for CYT387.